JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF) Sees Large Decrease in Short Interest
JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF – Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest ...
MM&M8d
Rx Rundown: Johnson & Johnson, Eli Lilly, the FDA and more
N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...
The Pharma Letter10d
Regenxbio inks MPS drugs collab with Nippon Shinyaku
Shares of US biotech Regenxbio surged 18.4% in pre-open trading Tuesday after announced a strategic partnership with Japan’s ...
Pharmabiz10d
REGENXBIO & Nippon Shinyaku enter exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
Rockville, Maryland Wednesday, January 15, 2025, 12:00 Hrs [IST] ...
BioPharma Dive10d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical ...
ENDPOINTS NEWS10d
Re­genxbio sells Hunter syn­drome li­cense with FDA fil­ing un­der­way
Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
biopharma-reporter11d
Regenxbio and Nippon Shinyaku collaborate to develop and commercialize gene therapies for Mucopolysaccharidosis I and II
The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and ...
bovnews11d
This Biotech Partnership Could Be the Catalyst REGENXBIO (RGNX) Needs—But What’s Next?
The partnership between REGENXBIO and Nippon Shinyaku is more than just a standard collaboration—it’s a bold, forward-looking venture aimed at bringing revolutionary gene therapies to market for rare, ...
REGENXBIO, Nippon Shinyaku Join For Development, Commercialization Of RGX-121, And RGX-111
REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for ...
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku
Shares of Regenxbio Inc . (NASDAQ: RGNX) surged 18.4% in pre-open trading Tuesday following the announcement of a strategic partnership with Nippon Shinyaku Co., Ltd. for the development and ...